Oops...Novartis Does It Again!
(2).jpg)
Earlier this week, I suggested in a post that pharma layoffs were beginning to decline whereas biotech layoffs were rising. And wouldn’t you know it, just when big pharma employees thought that their jobs were safe, the Swiss pharmaceutical giant Novartis today announced that it was laying off 2,000 US employees. According to a post on the Pharmalot blog, 1,630 sales reps and an additional 300 positions will be eliminated at Novartis’ Hanover, NJ US headquarters. Last fall, Novartis eliminated 1,100 jobs in Switzerland, 900 R&D and 1,400 sales reps in The US and another 550 jobs at a manufacturing site in the UK
While the announced layoffs may be part of a global downsizing effort that began last year, many analysts believe Novartis decided to reorganize because its new hypertension drug, Tekturna, performed poorly in clinical trials (increased incidence of non-fatal stroke, renal complications, hyperkalemia and hypotension) to garner approval of the drug to treat patients with Type II diabetes who are a greater risk of cardiovascular and renal events. The company’s best-selling hypertension medicine Diovan lost patent protection in Europe earlier this year and it due to expire in the US next September.
Company executives were betting on Tekturna to replace hypertension sales lost to generic competition for Diovan. Tekturna, approved in Europe as Rasilez, generated sales of $449 million during the first nine months of the past fiscal year but the poor clinical trials results suggest that it may be difficult for the drug to generate the $1.4 billion in annual sales (by 2016) forecasted by many financial analysts.
Stay tuned for more big pharma layoff updates!
Until next time...
Good Luck and Good Job Hunting!!!!!!
Much has been written about the emerging markets in China. While there are likely thousands of business article and white papers on China’s economic expansion, I was unable to find a single source that provided me with some vital economic and social statistics to explain China’s rise as an economic power; that is until I received OnWisconsin, a quarterly publication from my alma mater the University of Wisconsin-Madison.
In many cases, people looking for (1)(1).jpg)
Last week, US unemployment dipped to 8.6%, it lowest level since 2008. Stock markets rose and everyone was buoyed by a possible economic recovery. What a difference one week can make. Today, Astra Zeneca announced that it will layoff 1,150 sales reps; a few short weeks after announcing plans to eliminate 400 jobs at is US headquarters in Wilmington, DE. The company currently employs about 61,000 workers worldwide, including 14, 000 in North America..jpg)
Mark Senak, author of the 
Layoffs at big pharma tend to slow during the summer as most people are on vacation and nobody wants to fire folks when the kids are out of school. However, the failing economy has prompted several companies to abandon tradition and fire people during the summer anyway.
The tough job market and economy have caused lots of folks to consider changing careers to find gainful employment. While sometimes a career change is warranted, it may not be as easy as you think. With this in mind, there was a great article entitled.png)
.jpg)
Over the past several weeks, I have participated in various online conversations and discussions about the wisdom of getting a PhD degree in the life sciences. While the conversations have been wide reaching and, at times quite emotional, a common theme is beginning to emerge and I think that the time has come for me to weigh in on it. To wit, getting a PhD degree is not the best decision a person can make if he/she wants a guarantee of employment upon completion of his/her training.
The world’s largest generic pharmaceutical company Teva Pharmaceuticals Industries LTD today 
Depending upon the source, the cost of bringing a new prescription drug to market these days ranges from roughly $1.2 to 1.5 billion. While there is no question that clinical studies represent the most costly aspect of getting new drugs approved, the hidden costs—mainly promotion and marketing—are what actually inflate the costs of new drug development. Not surprisingly, drugmakers fail to disclose that these costs are included in the estimates for new drug development. If these costs were eliminated from the total, then the cost of developing new drugs will be significantly less than the current $1.2 to $1.5 billion price tag.
Last week’s special issue of Nature Magazine(1).jpg)
Mathew Herper, who writes at the Forbes Blog, 
For the past three years or so, Eli Lilly CEO John Lechleiter has publicly criticized America’s lack of math, science and engineering preparedness. Further, he has lamented that this lack of preparedness has resulted in a lack of innovation and that it threatens the US standing as a leader in the pharmaceutical and biotechnology industries. Finally, Lechleiter squarely places the blame on American science educators. 
While India and China have been getting much of the attention and press over the past few years, Latin America is quietly become a market to watch for the life sciences industry. According to industry analysts,.gif)
As many BioJobBlogger readers know, the life sciences industry is highly regulated. And, companies that market and sell drugs must be compliant with the Current Good Manufacturing Practices (CGMPs) mandated by the US Food and Drug Administration (FDA) and other regulatory agencies.
For the past few years, I have been 
By now, most BioJobBlog readers are aware that internships (paid or otherwise) have become a prerequisite at many companies to secure a full time employment. While I think internships are a great idea to jumpstart a career, not all internships are created equal or worth it. Put simply, it is up to the prospective intern to determine whether or not the advantages outweigh the disadvantages. Nevertheless, according to a report by the College Employment Research Institute three-quarters of the 10 million American students enrolled at four year colleges and universities will work as an intern before graduating. .jpg)
There is no question that Twitter is the new social media tool of the moment. And, it should come as no surprise that scientists and other bioprofessionals have been slow to jump on the Twitter bandwagon. While the jury is still out on Twitter’s effectiveness as a research tool, there is a growing body of evident that suggests that it can be a valuable tool when conducting a job search. 
I first heard about informational interviews two years ago at the Annual Biomedical Research for Minority Students (ABRCMS) at which I was reviewing resumes and offering career advice. I asked the student who mentioned the interviews exactly what they are. And, much to my surprise, I learned that the process involved approaching a “professional” to set up a meeting to discuss possible career paths at a company that a jobseeker was interested in. 
The Pharmalot Blog .jpg)
US Food and Drug Administration (FDA) inspections of drug and devices manufacturing facilities are typically anxiety ridden exercises that can strike fear into even the most seasoned quality and regulatory affairs professionals. And, most manufacturing facilities do not escape these inspections unscathed and are routinely cited, in many cases, for minor infractions..png)
Let’s face it; most scientists are lousy communicators. While this is not an inherited defect, the poor communication skills exhibited by most scientists are a direct result of a lack of emphasis placed on oral and written communication skills during their training. In fact, being a “good communicator” may actually hinder a scientist’s success as a world class researcher. After all, prematurely divulging information or breakthroughs may result in being “scooped by the competition” both in terms of winning grant monies and publishing first. Consequently, from a Darwinian standpoint, good communications skills are a trait that may actually be selected against because they more than likely will reduce the overall competitiveness and “fitness” of most research scientists..jpg)
There has been some buzz on LinkedIn and Facebook about an article that appeared in the March 3, 2011 issue of Nature Magazine. The article entitled 
Yahoo jobs pointed me in the direction of an .jpg)
Swiss pharmaceutical giant Novartis .jpg)
Little is published in the blogosphere about the life sciences industry in Canada. Because of this, many people think that Canadian scientists and other bioprofessionals may have fared better than their US counterparts. However, like the US, thousands of scientists and others have lost jobs throughout Canada during the almost three year global recession.
Despite what you may have been told, managing a career and finding new job opportunities is all about networking. Yes, I know that scientists and many other bioprofessionals loathe networking, but that is the way the game is played and if you want to win you have to play by the rules (written or otherwise).
Many of you may know that I started BioJobBlog four years ago. To date, I have posted close to 1300 articles and over 1.5 million people have visited the blog. While the fact that between 65,000-70,000 unique users visit the blog monthly is emotionally gratifying and rewarding, I have been self funding the venture since its inception and my operating expenses have sadly gone up! This, coupled with my oldest son starting college next fall (and my other son two years from now), I have come to the conclusion that I can’t afford to spend as much time on the blog as I would like. Put simply, I need to focus on paying jobs (not BioJobBlog) that help to pay the mortgage and defray the cost of supporting my family.
Despite assertions to the contrary, scientists are pretty much like most other people. They eat, sleep, work, party and for the most part are social creatures. Therefore, it should come as no surprise that scientists are also susceptible to hype and succumb to research “fads.” In my former life as an academician, these fads were not so obvious and, for the most part, they unobtrusively helped to advance scientific research. However, after I abandoned academia for the private sector, these fads became blatantly obvious to me. And, for the most part, were primarily driven by potential profits rather than advancing scientific knowledge for the common good.
After seven months of public bickering over an appropriate sale price, the NY Time .jpg)
According to a 
Believe it or not, employment opportunities are looking better in the life sciences industry. While this may be good news for some, the need for R&D scientists and sales representatives in the US is dwindling. The high cost and low ROI for R&D at most major pharmaceutical and biotechnology companies has forced life sciences executives to outsource many R&D functions that previously had been performed in house. Likewise, the inability of companies to bring novel, new medicines to market has reduced the need for pharmaceutical companies to maintain large sales forces. Put simply, there aren’t enough drugs to be sold to warrant large numbers of sales people trying to sell them! Given this backdrop, now may be a good time for bioprofessionals in these areas to consider new job opportunities and possibly new career paths. To that end, this post contains information about several biocareer developments sites (created by me) that may be helpful to bioprofessionals looking for work or new careers. 
Sometimes job candidates do the stupidest things during job interviews. Several years ago I begged a hiring manager to give an MD a second shot at a face-to-face job interview after he botched the first one. The hiring manager reluctantly agreed to give my candidate a second chance to redeem his poor performance during the first interview. After the interview, the hiring manager told me that he wasn’t going to extend a job offer to my candidate because he was “on call” the day of the interview and he kept on excusing himself to answer his pager. This happened almost 12 years ago before the cell phone–texting explosion became annoying pervasive. 
BioCrowd (
In press release today,
Over the past few years, life sciences companies have shed over 200,000 jobs. Unfortunately, downsizing at some of these companies may not be over yet. Nevertheless, companies are always looking to recruit new talent to keep up with normal job turnover rates or to replace highly specialized employees whose skills sets are essential to successfully running the business. Because many of these former life sciences employees possessed special or arcane talents and skill sets, advertising for their replacements using conventional methods like .jpg)
I have been professionally critiquing curricula vita (CV) for scientists for the past 10 years or so. While some are better than others, they all tend to suffer from the same problems and mistakes. This is mainly because scientists, unlike many other jobseekers, are rarely taught the “ins” and “outs” of resume writing. 
While I typically don’t subscribe to practice of unbridled self promotion, I could not pass on the opportunity to let my readers know that BioJobBlog made the "Top 50 Blogs About Careers in Science."
The Pharmalot Blog today.jpg)
There is no question that mobile apps are de rigueur and like other mobile devices users, life science researchers are beginning to regularly use them! After all, any innovation that can make the long hours spent doing laboratory research, easier, less time-consuming and enjoyable are likely to be welcomed by most researchers..jpg)
I frequently tell persons who attend my career development seminars that looking for a job ought to be a fulltime job in itself. Unfortunately, while this may be accurate, it generally is not feasible for many scientists who are working toward an advanced degree working towards an advanced degree (they are suppose to spend all waking hours in the lab). Increasingly, the life sciences job market is becoming extremely competitive and fierce and gainful employment is much harder to come by than any time in the past. And, regrettably, most life scientists—unlike a majority of their non-scientist counterparts—have little or no training to prepare them to conduct even a basic job search. 
Yesterday, Novartis, one of the world’s largest pharmaceutical company 
Unlike most of its competitors, which are downsizing operations, the Swiss drug maker Novartis 
In contrast with many of its competitors, which have layed off thousands of pharmaceutical employees over the past two weeks, Roche
I am certain that many of you may have noticed that the size of the life sciences industry is shrinking at an unprecedented rate. Big pharma companies flush with cash, near- empty pipelines and impending patent cliffs have embarked on a buying spree that is likely to continue for next years (or at least until the economy shows clear signs of resuscitation). Pfizer’s .jpg)
Late last Friday, Sanofi-Aventis
The Pharmalot Blog today reported that Abbott will be 
It is well established that many scientist are not particularly adept at social interactions and are notoriously poor at networking. Contrary to popular belief these deficiencies are not genetic and likely result from the erroneous notion that scientists don’t need career network to advance their work or careers.
The ever watchful Mark Senak of the highly informative 
Last week, the outsourcing firm Challenger, Gray and Christmas 
.jpg)
Jena Ellis who works over at 
We are now three years into one of the worst economic downturns in the history of the US. While the job market will eventually recover, don’t expect things to be the “way they were” before the recession. In other words, the job market has undergone a paradigm shift and new job seeking rules have replaced the old ones.
Regulatory affairs professionals (RAP) are by far some of the most important employees at pharmaceutical, biotechnology and medical devices companies. Without RAPs, the requisite regulatory documents would not be filed and new drugs and devices would not be approved for marketing and sale..png)
Over 70 percent of hiring managers and HR professionals routinely use Google to find out more about prospective job candidates. While many jobseekers know this and do everything possible to expunge deleterious and compromising information from a Google search on their names, some don’t know that Facebook profiles are a routine target of all Google searches. Consequently, hiring managers may have access to some personal information (including photos) that may jeopardize a job candidate’s prospects. .jpg)
There is no question that losing a job or facing the prospect of long term unemployment can have severe emotional and psychological consequences. Sadly, I came across a
When it comes to job searching, the curriculum vitae (CV) or resume is the most important document that a jobseeker must create. Despite the importance of this document, many jobseekers, especially graduate students and postdoctoral fellows, fail to give them much thought or put much time into creating them. In today’s economy, typos, poor grammar and too much information are certain to cause most hiring managers to take a pass on you as a job candidate. However, as Caroline Potter of Yahoo HotJobs describes in her article entitled “The Biggest Resume Mistakes You Can Make” there are more critical issues that must be considered and addressed when crafting a successful CV or resume. 
Unlike PhD-trained scientists, physicians and other healthcare professionals must be licensed to practice medicine and are annually required to participate in continuing medical education courses (CME), seminars and lectures. CME training is required by medical licensing agencies to insure that healthcare practitioners are update to date with the latest clinical practices and informed about medical development within their respective fields. 
I read a fascinating 
While Pfizer has rapidly elevated its standing in life sciences social media circles, the 
Unemployment in the US is still hovering around 10% and in some parts of Europe like Spain it is closer to 20%. In marked contrast, the unemployment rates in Australia (5.1%) Hong Kong (4.5%) and Singapore (2.2%) are much lower. With the exception of Japan, Asian economies have rebounded more quickly from the global recession than those in the West..jpg)
An article in today’s New York Times business section loudly proclaimed that the number of people using 
I came across this excellent article written by 
Under ideal circumstances, job interviews can be very stressful and emotionally draining. After all, how you perform on a job interview will likely determine whether or not you get an offer for a position. Unfortunately, unless you are an experienced jobseeker, who has has participated in many job interviews, you will likely be taken by surprise at your next one. To that end, the following tips, when adhered to, will likely help to reduce your stress level at your next job interview and possibly increase your chances of getting a job offer.
Johnson & Johnson’s McNeil Consumer Healthcare, already under Congressional investigation for selling allegedly tainted Tylenol, announced late Tuesday that it was recalling other products made in the Puerto Rico manufacturing facility in question.
John Lechleiter, PhD, chairman and CEO of Eli Lilly & Co. today told members of the Detroit Economic Club that the US is losing its competitive edge and that “evidence is mounting for an 
Johnson & Johnson is arguably one of the world leaders in bringing social media to the pharmaceutical industry. Marc Monseau and his dedicated team oversee a network of blogs, video channels and Twitter feeds while some of J&J’s brand companies even sponsor patient advocacy communities like ADHD Moms and ADHD Allies. However, the company’s recent handling of manufacturing problems and recall of Tylenol and other pediatric medicines seemingly flies in the face of openness and transparency; two of the underlying tenets and guiding principles of social media..jpg)
While most successful professionals want you to believe that they “fell into” their current jobs, the truth is that they wouldn’t have made it as far as they had without thinking or divining some type of strategic career plan. The trouble is that many early career professionals buy into this assertion—and rather than chart their own career trajectories—tend to gravitate toward jobs or job titles held by these seemingly successful professionals. .jpg)
Japanese drug maker Takeda Pharmaceuticals announced today that it will slash almost 
While most life scientists that I know have Facebook pages and profiles on LinkedIn, many fewer don’t use Twitter. Perhaps more troubling, many life scientists who have heard of Twitter aren’t exactly sure what it is. For those of you who may have spent too much time in the laboratory for the past two years, Twitter is a microblogging platform (limit 140 characters) that is taking the social media community by storm. Analysts predict that Twitter may become larger and gain a greater market share than Facebook; but I digress..gif)
There is no doubt that it is becoming increasingly difficult for persons with PhD degrees in the life sciences to pursue traditional career paths. To that end, Anne Miller of 
A common lament from that I frequently hear from graduate students and postdoctoral scientists at career development meetings is the need for "prior industry experience" to qualify and be considered for an industrial science job. Invariably, someone asks: “How in the world am I supposed to get industrial experience if nobody is willing to hire me as an industrial scientist?” Prior to the financial meltdown, I frequently advised PhD-trained scientists seeking industrial jobs to consider positions in smaller, local biotechnology companies.
There is a growing controversy over the rules governing whether .jpg)
One economic downturn and it seems as though the pharmaceutical world has been turned upside down! Who would have thought a few years ago that emerging pharmaceutical markets in India and Asia will outpace the US and Western European markets in the very near future (I did but nobody listens to me). To that end, Ranbaxy Laboratories .jpg)
According to a .jpg)
The recent economic downturn, coupled with the growing competition for jobs at pharmaceutical and biotechnology companies, has markedly increased the importance of internships as pre-requisites to gainful permanent employment. In the past, life sciences companies were willing to take a risk on promising new employees who did not possess any previous work experience. However, the glut of life scientists on today’s job market has empowered prospective life science employers to adopt a “let’s-try-them-out-before-we-hire-them” approach to employment. Like it or not, this is the way business is done these days.
AstraZeneca today announced that its Chief Executive David Brennan will receive no increase to his base salary this year, as the drug maker continues a freeze for top executives imposed last year due to weak economic conditions.
Medicis Pharmaceutical, the maker of Dysport a drug approved by the US Food and Drug Administration (FDA) to smooth skin furrows between the eyebrows, recently.jpg)
For the past year or so, I have been focusing on the downsizing and layoffs taking place at big pharmaceutical companies. The unprecedented size and scope of these massive layoffs have overshadowed the downsizing and job loss taking place at small to mid-size public and private biopharmaceutical companies. In contrast with most fully-integrated vertical pharmaceutical companies that are flush with cash, most biotech companies—even the likes of Amgen, Genentech, Gilead and others—don’t have the cash reserves to maintain operations in a down economy or when a drug candidate fails in clinical development. This coupled with the lack of venture and private equity capital has been causing biopharmaceutical employees to lose sleep in recent months..jpg)
In case you did not know, the .jpg)
During the past year,.jpg)
For the past decade or more multiple drug resistant strains of bacteria such as methicillin resistant Staphylococcus aureus (MRSA), enterococci and other Gram positive cocci have been highlighted and showcased in the medical and lay press. While the incidence of infections caused by MRSA and other Gram positive cocci has steadily risen, antibacterial drug discovery experts have long known that the greatest disease threat in the future will be from emerging multiple antibiotic resistant strains of Gram negative bacteria including Acinetobacter baumannii, Klebsiella pneumoniae, Serratia marcescens and Pseudomonas aeruginosa..jpg)
American competitiveness in engineering, technology and science. Unfortunately, while American competitiveness and innovation in these areas continues to wane, little has been done (except talking) about it! 
In previous 
Despite the announcement late last week in the London Sunday Times that 
.jpg)
I Am Biotech.jpg)
It’s no secret that pharmaceutical and biotechnology companies are “not in love” with social media. However, whether life sciences company like it or not, social media is beginning to affect human clinical testing with an increasing number of patients demanding access to unapproved experimental drugs to treat life-threatening illnesses. .jpg)
Harrison Ford’s new movie “Extraordinary Measures” (also starring Brendan Fraser) is loosely based on 
Pfizer .jpg)
Last week, the market-analyst firm 
I previously posted several articles on 
Many progressives and left-leaning individuals (like me) voted for President Obama because he presented himself as somebody who will stand up for what he believes. Until recently, I, along with others, have been deeply disappointed in his performance and it was no longer clear to me what he truly believes in. However, his recent stand on healthcare reform (sadly without a public option), his performance at the global warming summit and most recently his quick response and unequivocal support for Haitian earthquake victims suggest to me that we are finally beginning to see what President Obama believes and what he is made up. To that end, Obama has .jpg)
It is getting difficult to keep track of the job cuts that are happening almost daily at Pfizer. A quick perusal of the job cuts to date indicate that the company has eliminated about 1200 jobs in the past week;.jpg)
I am frequently asked by graduate students and postdoctoral fellows who are having trouble finding a research and development job, whether or not it makes sense to go to business school to get an Masters of Business Administration) MBA degree to enhance their business acumen. While I don’t think it would hurt (especially if you are interested in business), I also don’t think most scientists benefit from enrolling traditional MBA degree programs. With this in mind, some forward-looking academic institutions have launched joint PhD-MBA programs which allow students enrolled in these programs to graduate with PhD and MBA degrees at the end of their graduate training..jpg)
Just when you thought that holding on to a job couldn’t get any worse, Pfizer .jpg)
For many years, I taught medical students that the emergence of antibiotic resistant strains of bacteria primarily resulted from the overuse and misuse of antibiotics by physicians. While this seemed to make sense, I started chatting in the late 1990s with 
Novartis AG 
The public hearing held by FDA last week in Washington DC to address social media and promotional advertising in the pharmaceutical seems to have altered the agency’s perspective on all things digital. Today, according to a
Much has been written about how supportive the pharmaceutical industry has been about US healthcare reform. Prior to the debate, the Obama administration gleefully announced that pharma will give $80 billion in drug discounts in exchange for certain assurances that weren’t publicly disclosed. As most of us know, the US House of Representatives passed historic healthcare reform legislation last week and in addition to a public option it stipulates that pharma will be required to give $140 billion in drug discounts. According to Ed Silverman over at the newly reinstated .jpg)
Unlike many of my social media colleagues, I’m not attending the FDA public hearing taking place in Washington, D.C today (Friday the 13th oh my). I wanted to attend and actually testify but I didn’t understand how the process works and blew my opportunity. However, I will be prepared for rounds 2 and 3 and beyond. I can assure you that this will not be the last public meeting organized by the agency to develop guidance for the use of social media in pharmaceutical marketing and advertising. 
For the past 10 years or so, I have been providing career counseling and development seminars and workshops for life scientists. In the early years, students, postdocs and a smattering of faculty members would attend to learn about industry trends, the job market and more recently, alternate careers for PhDs and postdoctoral fellows. However, over the last few years, a disturbing trend has emerged—the lack of .jpg)
I just returned from the 
Over the past year or so, more graduate students and postdoctoral fellows have been asking me about management consulting careers in the life sciences. I spent several years working as an independent management consultant and while it was a great experience the revenue stream was unreliable at best and the ability to work was highly contingent upon the economy. However, I can assure that my experiences as an independent management consultant were marketing different than those of consultants who work at the consulting firms like McKinsey or the Boston Consulting Group. For those of you interested in life style of a high-powered management consultant I highly recommend you visit their websites for more info. 
I am attending the 
I suspect by the growing numbers of people who read BioJobBlog, that some of you may be beginning to wonder who I am. While nobody has taken me to task about my credentials or musings to date, I figured it may be worthwhile to share my “story” with those BioJobBlog readers who may be at a crossroads in their careers. I credit my graduate school experiences and PhD degree for the tenacity, perseverance and the ability to reinvent myself during an eclectic, and oft times, circuitous career path. 
I received a call today from GDS International, a UK-based b2b publishing company, alerting me to its annual, event called the 
Whenever I do resume critiquing at scientific meetings, someone always asks about how to negotiate a job offer. Most of the people that ask the question aren't even close to receiving a job offer and I do my best to deflect the question. However, at a recent meeting, I spent 30 minutes with a PhD student who had received an offer advising him on how to get a better deal from his prospective new employer. This got me thinking and I invited Joe Tringali, a veteran recruiter with lots of negotiating experience to write a blog post about strategies and things to consider when negotiating a job offer.(1).jpg)
The fourth quarter is over, earnings are being announced and new budgets for the upcoming fiscal year are being evaluated and tweaked. This means that we have officially entered layoff and closure season. Isn’t it great that big companies wait until right before the holiday season to let employees know whether or not they will have a job next year?
I don’t want to brag but I have been touting career options in health informatics and health information technology (HIT) for the past year or so. Today, I came across a post by CareerBuilders declaring health informatics and HIT are the hottest new career trends to hit the market in recent years. .jpg)
An annual survey conducted by Science magazine and the American Association has identified the 
In a previous post I 
I came across a .png)
For the first time in history, more people are searching the Internet for health information than asking doctors. Web 2.0 and social media tools are allowing people to discover new ways to connect, learn and engage one other in search of healthcare and drug information.(3).jpg)
Mark Senak at the.jpg)
I previously posted an 
Mark Senak who runs the
Sepracor shareholders may be able to sleep better at night without the aid of the company’s top selling insomnia drug Lunesta after agreeing to be purchased on Thursday by Dainippon Sunmitomo Pharma of Japan. Dainippon will pay $2.6 billion for the rights to Lunesta and other drugs in Sepracor’s pipeline. 
in today’s New York Times lamenting the marketing practices utilized by drug companies to inform physicians about their products. While these practices may be troubling to legislators and the American public, everybody who works in the life sciences industry including regulatory agencies like the US Food and Drug Administration (FDA) understands the “rules of the game” and how it is played. However,.jpg)
Mark Sendak, author of the incisive .jpg)
Twitter is arguably the hottest new platform to hit the social media scene is the past five years. Twitter devotees are convinced that anything is possible if the microblogging platform is used correctly. In today’s economy, the most pressing need for many people is finding a job. While Twitter is effective for branding, marketing and occasionally some witty intellectual exchanges, its usefulness for jobseekers has yet to be demonstrated. To that end, there was a recent instructional case study on TwiTip—.jpg)
Losing a job is a BIG deal whether you were layed off, fired or right-sized out of it. Not only do you have to worry about health insurance, bills and paying rent or making a mortgage payment, you must also deal with a myriad of self esteem and emotional issues that frequently arise after losing a job. While there are many articles and books that describe how to functionally conduct a job search after being layed off, there are only a handful that discuss how to cope with the stress and negative emotions that frequently accompany job loss..gif)
Under ideal circumstances, job interviews can be very stressful and emotionally draining. After all, how you perform on a job interview will likely determine whether or not you get an offer for a position. Unfortunately, unless you are an experienced jobseeker, who has has participated in many job interviews, you will likely be taken by surprise at your next one. To that end, the following tips, when adhered to, will likely help to reduce your stress level at your next job interview and possibly increase your chances of getting a job offer..png)
During my recent trip to Vermont and Woodstock, NY I had several conversations about Twitter. Surprisingly, I was being asked to explain Twitter to my nephews, both of whom are in their early 20s and to family friends who are in their late 40s and beyond. Also, at several recent science career fairs that I attended many graduate students and postdocs had never heard of Twitter or it they had, they don’t use it. Initially, this was puzzling but after considering the most recent Twitterverse demographics –I think the average age of Twitter users is around 35 to 40—it made more sense to me..jpg)
Reuters reports 
Back in the late 1990s, applying for jobs online was all the rage! The technology was new and fresh and applying for jobs online was fast and easy. Companies raced to build corporate websites for prospective job applicants, major job boards like Monster and Careerbuilder were launched and human resources professionals though they were ushering in a “new era of employee recruitment and retention.” While applying for jobs online once seemed like a panacea for both job seekers and corporate employers, it never has lived up to all the fanfare and hype!
It’s no secret that major pharmaceutical companies are .jpg)
Over the past few years, a number of search engines designed for the life sciences have appeared. I thought it might be informative for BioJobBlog readers to list some of the more popular ones and how they are used. I want to warn you in advance that this is not a comprehensive list. That said, if I’ve inadvertently omitted your favorite search engine, please feel free contact me or simply list it in the comments section for this post..jpg)
Back in the day—when the economy was sound and jobs were plentiful—an adequately written resume with a sprinkling of keywords and strategically-placed human resources clichés were sufficient to get your foot in the door at most companies. However, in today’s troubled economy where unemployment is rampant, there are certain buzz words and phrases that no longer resonate with hiring managers. According to Liz Ryan, an experienced corporate career advisor who writes for Yahoo Hot Jobs, the following phrases must never appear in a resume if you are a job seeker in today’s market. .jpg)
Amber Johnson at 
Mark Senak, who writes the outstanding .jpg)
Word on the street suggests that Roche has severed its relationship with the Pharmaceutical Manufacturers of America (PhRMA) the trade group that represents and lobbies on behalf of the pharmaceutical industry. The recent purchase of Genentech must have convinced the venerable 100 year old pharmaceutical company that proteins not small molecule drugs are the key to its future.
While life sciences companies are still reluctant to take the “social media plunge,” many other companies (with active social media programs) frequently hire employees known as social media managers who oversee and run their social networks. This is because successful social media websites require daily attention and are extremely time consuming and labor intensive. In general, employees who are hired for these jobs have strong backgrounds in social media and technology but frequently possess little expertise in the industry that they are working in. Because social media is so new, many hiring managers believe that the social media and technology skills of these managers are more important than an understanding of the industry that they work in. However, while this practice may be acceptable in other industries, it won’t be the case for the social media managers who oversee pharmaceutical, biotechnology and medical devices and diagnostics social media websites. These managers will likely be required to have a firm understanding of current rules and regulations guiding drug development and marketing and advertising of approved life sciences products. This will be necessary if the drug makers who hire these managers want to steer clear of regulatory scrutiny by the US Food and Drug Administration and other regulatory agencies.
From time to time, I come across some interesting facts and statistics that are worth noting. This month’s issue of Pharmaceutical Technology Europe offered several things that were blog-worthy. Here they are: 
GlaxoSmithKline (GSK) inked a deal yesterday with the Indian generics manufacturer Dr. Reddy’s Laboratories giving it access to over 100 future generic drugs and a gateway to Asia’s emerging pharmaceutical markets. The therapeutic areas covered under the agreement include diabetes, cardiovascular, pain management, gastroenterology and oncology. Dr Reddy’s Laboratories is one of India’s largest generic drug manufacturers. Like many of its competitors, Dr. Reddy’s Laboratories also have active development programs for new biotechnology drugs and biosimilar products..jpg)
As many of you may know, I attend national science meetings where I offer resume critiquing services and give career development seminars on topics ranging from resume writing to alternate career opportunities for life scientists. Frequently, I critique the resumes of 
A much-anticipated 
After yesterday's post about career planning for life scientists, one of my soon to be former students in the Fundamentals of Bioscience Program aptly pointed out that my readers might have benefitted more if I had, in fact, offered information about alternate career possibilities for bioscientists. I don't want the student to get too overconfident but I had the same thought immediately after I uploaded the post. 
Yesterday, I gave a lecture entitled “Alternate Careers: Taking the Road Less Traveled” to over 100 members of the University of Pennsylvania’s Biomedical Graduate Student Association. As always, there were many good questions and comments during and after the presentation. Some of the career anecdotes offered by several of the students reminded me of a conversation that I had several weeks ago with one of my Fundamentals of Bioscience students—I teach a Product Development and Regulatory Affairs course in the program—who refreshed my memory about a typical graduate student approach to career development and job searching. “We don’t think about jobs or our careers until we begin writing our PhD theses” she said. “Until then, our advisers don’t talk about careers or jobs and only bring it up because our funding will run out” she added. Admittedly, I had forgotten this because so many years have passed since my graduate student days. That said, it forced me to consider how much the life sciences job market has changed since I was graduate student and how vitally important it is for today’s graduate students to think about and possibly explore different career options throughout the course of their graduate training..jpeg)
After months of complaints by university officials and scientific organizations, the US State Department .gif)
Over the past three years, more than
The National Institutes of Health (NIH) announced on Wednesday that it was creating a new program aimed at “finding treatments for some of the 6,800 rare diseases that collectively affect about 25 million Americans.” 
Medtronics, the world's largest medical-device company, 
Pfizer, the world’s largest drug maker, announced on Thursday that it is unveiling a new program that will let people who have lost their jobs and health insurance to keep taking Pfizer medications — for free, and for up to a year. The company will provide more than 70 of its prescription drugs ranging from Viagra to Lipitor at no costs to unemployed and uninsured Americans who lost their jobs since Jan. 1 and have been taking Pfizer drugs for me than three months. It is not clear how much Pfizer will spend on the program and whether or not costs will be capped..jpg)
Are you a life sciences or healthcare professional with a passion for computers, IT or software development? If so, you might want to consider a career in health informatics—one of the hottest, new fields in the life sciences and healthcare industries. Health informatics specialists typically have expertise in medical records and claims, clinical care and programming. In other words, they have a foot in two worlds— medicine and technology — and can easily bridge the often daunting gap between them. It is important to point out that there is a difference between healthcare IT and informatics personnel. The health IT people run the servers and install software, but the informatics people are the ones who analyze and interpret clinical/ medical information and work with clinical and other healthcare staff to advise and help them..jpg)
Earlier this week, the US Food and Drug Administration (FDA) sent 
Using Facebook and Twitter to find jobs is becoming routine in many industries including healthcare. However, the life sciences industry is lagging behind most others when it comes to social media and recruitment. Nevertheless, many companies and academic institutions are beginning to realize that Facebook (FB), Twitter and other science social networks are good source of qualified candidates for those difficult-to fill job openings. 
The US economy has lost about 7.1 million jobs since December 2007 and nationwide unemployment is hovering around 8.5 percent. Despite the lost of about 80,000 pharmaceutical jobs over the past three years and unprecedented consolidation taking place in the life sciences sector—Merck-Schering Plough, Pfizer-Wyeth and Roche-Genentech—the job prospects for scientists at biotech companies, medical devices and diagnostics, and government appear to be stronger than anticipated. While drug discovery and sales jobs may be scare, there are rapidly emerging opportunities in the fields of medical communications, regulatory affairs, biomanufacturing, clinical trials management , bioengineering, medical devices/diagnostics and website development and management..jpg)
Previously, the US Congress proposed legislation to create a regulatory approval process to allow the Food and Drug Administration (FDA) to approve generic versions of blockbuster biotechnology drugs known as follow-on biologics (FOBs). While a regulatory pathway exists for approval of generic versions of small molecule drugs (as outlined in the 
As many of you know, the life sciences industry, one of the most highly regulated industries of the economy has been hesitant and reluctant to embrace social media to reach out to patients, physicians and the lay public. This is because the US Food and Drug Administration, specifically Division for Drug Marketing, Advertising and Communications (
The old baseball adage which says that “you can’t tell the players apart without a program” is particularly apt when it comes to tracing the M &A activity that led to the creation of some today's largest pharmaceutical companies..jpg)
Facebook contends that it has over 175 million members, making it the largest social network in the world! Interestingly, according to an .jpg)
A team of researchers at the University of Wisconsin-Madison (my alma mater) genetically engineered a strain of Streptomyces platensis to 
How many of you read the printed ingredients and nutrition fact boxes found on packaged foods to help you decide which of two similar products you ought to buy? What if the same concept was applied to direct-to-consumer (DTC) prescription drug ads? Do you think that it would be easier to determine which of two similar medications may be best for you? Well, researchers at Dartmouth Medical School think so! And, they are urging the US Food and Drug administration to adopt a similar concept for all DTC advertising..gif)
I have been accumulating anecdotal information about companies,organizations and institutions that use social media tools like Facebook, Twitter YouTube etc. I decided to attempt to conduct an informal survey to determine whether or not the life sciences sector is adopting and embracing social media to meet its objectives (whatever they may be). .jpg)
The .gif)
About a year ago, I was eating lunch and bunch of pharma executives were at the table next to me. I inadvertently overhead bits of their conversation and I heard the words, Facebook, MySpace and YouTube mentioned. This suggested to me that pharma was more aware of social media (and its business implications) than pharma publicly cared to admit. Pharma has been reluctant to embrace social media because of possible legal and regulatory ramifications. Nevertheless, a few companies have decided to boldly go where no pharma company has gone before—to YouTube..jpg)
Today is a sad day in the pharmaceutical and biotechnology blogging world. Pharmalot, a two year old, pioneering blog created by the intrepid Ed Silverman and the Star Ledger News has decided to call it quits. Unfortunately, the Star Ledger is in dire financial straits and it could no longer provide Ed with the support he needed to continue to run the Pharmalot blog. Please read .jpg){kind=small}
.jpg)
In a .jpg)
The relationship between science, education and industry has always been a tenuous one. To learn more about the complexity of this relationship check out this .jpg)
I know this is kind of odd, but I have recently begun to wonder which life sciences companies have layed off the most employees this past year. Well, for those of you out there who were also wondering we don't have to wonder any longer because Ed Silverman over at the Pharmalot blog has conveniently compiled a 
It seems that every day a new American industry asks the US government for a bailout because of impending financial exigency. That said, I was somewhat surprised to learn today that the.jpg)
Recently, I have come across posts on blogs and websites reporting on lay offs and cost-cutting measures that are taking place at some biotechnology companies. A good example of this is a post that appeared yesterday on the Fierce Biotech Web Site. The headline read: 
According to a .jpg)
I first thought about starting a social network for life sciences professionals about a year ago after joined I Facebook and LinkedIn and then learned about SciLink, one of the first social networks for scientists. Apparently, others had the same idea and today, there are currently, by my reckoning, no fewer than 20 social networks for scientists—each promoting a unique approach to networking for scientists..jpg)
The other day I was chatting with .jpg)
I want to let my readers know that a beta-version of .jpg)
.jpg)
ou all know by now, American pharmaceutical companies have been intermittently laying off thousands of employees for the past two years or so. Many of the employees who have lost their jobs are R& D scientists, marketing personnel and sales representatives. This seemingly makes sense—because fewer drugs are being discovered and brought to market, fewer people are required to market and sell them. That said, isn’t discovering new drugs the currency and lifeblood of the pharmaceutical industry? How do these companies plan to stay in business if they continue to layoff employees who are seemingly responsible for developing new sources of revenue for them? Taking their cues from the IT and software industries, many US drug makers are beginning to either transfer R&D operations to foreign, company-owned research facilities or outsourcing some or all R&D activities to foreign contract research organizations (CROs).
I was reading Karen Ventii’s 
.jpg)
On the heels of yesterday’s announcement that it wants to buy Genentech, Roche, in a surprise move, 
The social development of the web 2.0 has largely bypassed science. Hugely popular websites such as Facebook, MySpace, Twitter, Digg, Delicious and the like have millions of members and generate huge amounts of traffic. But those who use these sites come from all walks of life. None are devoted solely to science. 
In an attempt to assuage the jitters and financial concerns of investors who own stock in pharmaceutical, biotechnology and medical device companies, the US Food and Drug Administration announced yesterday that it will be change the format of the letter received by companies whose products are not ready for approval.
Last year was a 
Just when you thought things couldn’t get any stranger, a new pharmaceutical assessment tool called the 
.jpg)
I was contacted by the 
.jpg)
This is the first installment of 
ecruiter blog 
When I was working as a recruiter, I always called my candidates a day before a scheduled face-to-face job interview. I did this to reassure them, build confidence and provide them with any insights that I may have had regarding the hiring manager or the job. But, more importantly, I called to insure that they were adequately prepared to go on the interview. I typically talked with them about dress, interview etiquette, cell phone usage, body language etc. Sometimes, when I was concerned about particular candidates, I even sent (via fax or e-mail) an interview preparation checklist. 
Much has been said (and written) about the impact and power of a firm handshake in business settings. Are the urban legends and "old wives tales" really true? Peggy McKee .jpg)
.jpg)
There’s a ton of stuff online about .jpg)
Pfizer the world’s largest and least innovative pharmaceutical company 
About five years ago, a friend of mine and I had an idea to form a non-profit dedicated to providing consumers with information regarding the safety of marketed pharmaceutical and biotechnology medicines. At the time, we observed that consumers were repeatedly being misinformed about the safety and efficacy of many products, most notably follow-on biologics aka biogenerics. Unfortunately, we could not garner enough interest or financial support to get the organization off the ground. I guess that we had a good idea, but, as usual, were a little ahead of our time. A new organization called 
I just returned from my career development sojourn at this year’s FASEB meeting in San Diego, CA. Not surprisingly, all of my sessions were well attended. In fact, attendance at many of the presentations was standing room only. Again, this was not terribly surprising because the job market for graduate students and postdoctoral fellows for the last 5 years has been dismal. However, in contrast with past years, there was a noticeable and palpable difference in the attitudes of many of the students and postdocs who attended the sessions. In previous years, many career development participants seemed resigned to the possibility of a “jobless future”. However, this year there was a small but vocal group of participants who openly expressed their anger and resentment at the possibility of not finding a job after completing their training. I think that many graduate students and postdoctoral fellows have begun to realize that they are being exploited by a fundamentally flawed academic system and that they are “not going to take it anymore.”
I am sitting in Newark Airport waiting for my flight to San Diego which, not surprisingly, has been delayed for about 2 hours. As you might have guessed from the title of this post, I am on my way to the 2008 FASEB Career Development Symposium which is run every year at the annual FASEB meeting. 
Genzyme Corp announced yesterday
The hard work you that invested in your resume has finally paid off–you just received a call from the ACME Biotech’s Human Resources Department inquiring about your availability for a face-to-face interview with the company. After about 30 seconds of elation and joy, fear and anxiety begin to creep into your psyche-“OMG, an interview, this is my first one, what am I going to do?” 
Cambridge, MA-based 
FDA approvals of biopharmaceutical products have decreased in recent years. This includes recombinant proteins and monoclonal antibodies and cancer therapeutics. In the decade from 1996-2005, an average of 16.6 new drugs were approved each year. In marked contrast, there were only 11 and 12 new medications approved in 2006 and 2007, respectively. .jpg)
According to a .jpg)
to set up manufacturing and research operations in Ireland? In my opinion, the recent Irish pharma and biotech explosion has little to do with luck and everything to do with strategic vision, excellent planning and a well trained, inexpensive workforce.
.jpg)
Bristol-Myers Squibb announced today.jpg)
downward turn. Even the recession-proof pharmaceutical industry has taken a huge beating over the past year or so– and things seem to be getting worse! The biotechnology industry, which is highly dependent upon venture capital and private equity to remain healthy, is also trending downward and will be hit hard if the economy slides into recession. To make matters worse, the US Department of Labor recently released figures which showed projected growth (for 2006 to 2016) for the fastest-growing occupations in America (see below). Not surprisingly, scientists–industrial or academic– did not make the top 20 list.
Over the past 30 years or so, the vast majority of chief executives in the drug business have made their way to the top via the sales and marketing departments. Few senior executives have toiled in a research laboratory or for that matter, know the difference between NMR and protein purification. However, things may be changing in the industry. A quick perusal of the CEOs of the top 20 pharmaceutical and biotechnology companies (see below) reveals that 11 of 20 have degrees in engineering (4), medicine (2) and science (5). The remaining 9 have degrees in business and finance (3), sales and marketing (4) or law (2). Several of the scientists (2), engineers (3) and one physician also earned MBA degrees.
The Wall Street Journal Online published an 
